Valeant (VRX) Price Target Reduced at Deutsche Bank

July 31, 2014 3:08 PM

Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and reduced its price target to $128.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found